Navigation Links
Results from 8 late-breaking clinical trials presented at Heart Failure 2009
Date:5/30/2009

Results and updates from eight studies were presented during a late-breaking trials session at Heart Failure 2009. Reviewing them at a press conference, Professor John McMurray, President of the Heart Failure Association, described the trials' objectives and main implications.

A multicentre study of a new inotropic drug (which increases the contraction and pumping of the heart), CK-1827452, found that it increases systolic function in stable heart failure patients and was well tolerated in a proof of concept study. CK-1827452 is a new drug in a class known as Selective Cardiac Myosin Activators. Bigger trials are now needed to assess safety and effect on clinically meaningful endpoints.

Pre-RELAX-AHF is another proof of concept study with an interesting new vasodilator drug (relaxin), a hormone produced by the ovaries and placenta during pregnancy which causes expansion of the cervix and uterus. Because relaxin also relaxes arteries and veins, it reduces the resistance to bloodflow in these vessels - and hence the work the heart has to do to pump blood through them. Results of this trial are encouraging and showed that relaxin given for 48 hours produce rapid and sustained improvement in breathlessness and other heart failure symptoms, with a favourable impact on clinical outcomes at 60 days. Again, bigger trials are now needed to assess safety and effect on clinically meaningful endpoints.

CHANCE (Congestive Heart failure: A multidisciplinary Non-pharmacological approach for Changing in rE-hospitalisation and prognosis) is an important study from Russia looking at whether post-discharge non-pharmacological interventions by nurses and other health professionals could reduce the risk of hospital readmission. The study found that an approach of patient education and active follow-up (added to optimal medical care) decreased morbidity and mortality. This reinforces the findings of previous studies in other countries and suggests that
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Brooke Franchise Corporation Announces Selected July Results
3. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
4. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
5. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
6. NBTY Announces Preliminary Unaudited Net Sales Results For August 2007
7. Martek Announces Third Quarter 2007 Financial Results
8. MDS Reports Third Quarter 2007 Results
9. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
10. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013) Aortic arch pulse wave velocity, a ... of disease of the vessels that supply blood to ... the June issue the journal Radiology . ... functional information about vessel compliance that may help determine ... said Kevin S. King, M.D., assistant professor of radiology ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Applied PilotFish ... announced today that it has added support for the ... IDE, the eiConsole for Healthcare. In addition to the ... as LLP, FTP, and Web Services, it now offers ... Direct Protocol is a specification of the Direct ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
(Date:5/23/2013)... Aero Fulfillment Services, a national provider of ... to be the sole fulfillment provider for Olivenol® plus ... Brad Cole, CEO New Wave Biosciences said, “We chose ... location, e-commerce experience with both of our key audiences ... that will expand as our distribution grows.” He ...
(Date:5/23/2013)... Each month Dwell magazine is filled with ... electric cars. Nowhere in America are these pages more scoured ... capital. Thankfully this June, Green Car Journal is bringing its ... Dwell on Design 2013 ( http://www.dwellondesign.com ), America’s ... days of Dwell on Design, June 21-22, attendees and media ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2Health News:NewWave Biosciences Chooses Aero Fulfillment for e-Commerce Distribution of New Product to Reduce Inflammation 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5
... the lymph nodes also, according to a recent research, led ... immune response. // ,The dreaded disease is ... and the immature parasites travel to the animal's liver. Once ... liver cells and infect red blood cells, beginning the onset ...
... the teenaged girls in the UK are virtually starving themselves to ... Agency and Sugar magazine. // Some of these girls are reported ... 50 per cent always skip breakfast and do not know what ... they eat ‘as little as possible,’ while ten per cent said ...
... risk factors like blood pressure, age and medical history. Those who ... can be treated as outpatients, according to a publication in ... abrupt blockage of an artery due to a blood clot, or ... major health hazard. This is not fatal in the case of ...
... many as 20% of the men in the US suffer ... other diseases, including heart diseases. // The number of visits ... was introduced in 1998. The data available from the National ... S. Saigal and his colleagues. ,About 2,126 men ...
... that as many as 250,000 Scots are unable to access ... Health Department had drawn up an emergency care plan which ... as ?1.5 million has been allocated for this. The situation ... 10% of the population having to wait for a period ...
... a survey in 5 European countries on how women lead ... to find out whether women enjoyed the present life ... the work was funded by Economic and Social Research Council. ... have problems with their family life. ,Researchers found ...
Cached Medicine News:Health News:Malaria Can Develop In Lymph Nodes Also 2
(Date:5/23/2013)... 2013  Echo Pharma Acquisition Limited ("Royalty Pharma") announced ... Acceptance Threshold from 90 percent to 50 percent of ... accordance with the terms of the Revised Offer Document ... Under the terms of the Increased Offer, Royalty ... ELN ) for $12.50 per share in cash. The ...
(Date:5/23/2013)... 2013 Nederland keurt als eerste ... geassocieerd met BPH Astellas Pharma ... Pharma Inc, gebaseerd in Tokyo ... dat het Nederlandse College ter Beoordeling van Geneesmiddelen (CBG) ... De handelsvergunning verleend voor VESOMNI is voor "de ...
(Date:5/22/2013)... LAGUNA HILLS, Calif. , May 22, 2013 /PRNewswire/ ... is developing a medical device that will help alleviate ... preeclampsia. APT,s targeted apheresis cartridge is expected to be ... a leading cause of maternal and fetal death. ... in the United States . It ...
Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2
... YORK, Sept. 16 Reportlinker.com announces that ... in its catalogue: Prosthetic ... Assessment and Market Forecasts to 2016 ... Prosthetic Heart Valves - Global Pipeline Analysis, ...
... MedClean Technologies (OTC Bulletin Board: MCLN ), ... and disposal of medical waste and the destruction of ... signed a distribution agreement with Trojan Energy Systems, Inc., ... years of combined experience in the sale and service ...
Cached Medicine Technology:Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 2MedClean Technologies Signs Distribution Agreement with Trojan Energy Systems 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: